Generic Name and Formulations:
Reteplase 10.4Units (18.1mg); per vial; lyophilized pwd for IV inj after reconstitution; preservative-free.
Chiesi USA, Inc.
Indications for RETAVASE:
Management of acute myocardial infarction (AMI) to improve ventricular function and to reduce the incidence of congestive heart failure and mortality.
Start as soon as possible after onset of AMI symptoms. 10Units as IV bolus over 2 minutes; repeat dose 30 minutes after initiation of 1st bolus.
Active internal bleeding. History of cerebrovascular accident. Recent intracranial or intraspinal surgery or trauma. Intracranial neoplasm, arteriovenous malformation, or aneurysm. Bleeding diathesis. Severe uncontrolled hypertension.
Avoid noncompressible arterial puncture, internal jugular and subclavian venous punctures, IM inj, nonessential handling of patient to minimize risk of bleeding. Discontinue concomitant anticoagulant therapy if severe bleeding occurs. Recent major surgery. Cerebrovascular disease. GI or GU bleeding. Hypertension. Left heart thrombus. Acute pericarditis. Subacute bacterial endocarditis. Hemostatic defects. Severe hepatic or renal dysfunction. Hemorrhagic ophthalmic conditions. Septic thrombophlebitis. Occluded AV cannula. Elderly. Pregnancy (Cat.C). Nursing mothers.
Bleeding risks increased with heparin, vitamin K antagonists, aspirin, dipyridamole, abciximab. Coagulation tests may be unreliable during therapy.
Tissue plasminogen activator (tPA).
Bleeding, hypersensitivity reactions, GI upset, hypotension, fever; cardiogenic shock, arrhythmias, AV block, pulmonary edema, heart failure, cardiac arrest, ischemia, reinfarction, myocardial rupture, mitral regurgitation, pericardial effusion, pericarditis, cardiac tamponade, venous thrombosis, cholesterol embolism, electromechanical dissociation.
Kit—1 (2 vials w. diluents, supplies)
Half-Kit—1 (1 vial w. diluent)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML